H
Hua Tu
Researcher at Amgen
Publications - 4
Citations - 4182
Hua Tu is an academic researcher from Amgen. The author has contributed to research in topics: CYP8B1 & Farnesoid X receptor. The author has an hindex of 4, co-authored 4 publications receiving 3891 citations.
Papers
More filters
Journal ArticleDOI
Identification of a Nuclear Receptor for Bile Acids
Makoto Makishima,Arthur Y. Okamoto,Joyce J. Repa,Hua Tu,R. Marc Learned,Alvin Luk,Mitchell V. Hull,Kevin D. Lustig,David J. Mangelsdorf,Bei Shan +9 more
TL;DR: Results presented here show that bile acids are physiological ligands for the farnesoid X receptor (FXR), an orphan nuclear receptor, which demonstrates a mechanism by which bile acid transcriptionally regulate their biosynthesis and enterohepatic transport.
Journal ArticleDOI
Role of LXRs in control of lipogenesis
Joshua R. Schultz,Hua Tu,Alvin Luk,Joyce J. Repa,Julio C. Medina,Leping Li,Susan Schwendner,Shelley Wang,Martin Thoolen,David J. Mangelsdorf,Kevin D. Lustig,Bei Shan +11 more
TL;DR: The identification here of a synthetic, nonsteroidal LXR-selective agonist series represented by T0314407 and T0901317 revealed a novel physiological role of LXR, and suggested that the increase in plasma lipids occurs via NXR-mediated induction of the sterol regulatory element-binding protein 1 (SREBP-1) lipogenic program.
Journal ArticleDOI
FXR, a bile acid receptor and biological sensor.
TL;DR: This work has shown that the nuclear farnesoid X receptor (FXR) constitutes a potential therapeutic target that can be modulated to enhance the removal of cholesterol from the body.
Patent
Treatment of hypertriglyceridemia and other conditions using LXR modulators
TL;DR: In this article, a method for identifying compounds that are suitable for use in modulating fatty acid and triglyceride biosynthesis, and thus treating conditions such as hypertriglyceridemia and lipodystrophy, among others.